Sirius Therapeutics

Sirius is a forward-thinking biotech company that is focused on creating new RNAi (RNA interference) therapies for international markets. RNAi is a biological process where RNA molecules inhibit gene expression, effectively "silencing" targeted genes. This technology is used by Sirius to develop innovative treatments for cardiovascular diseases.

The company has recently received approval from China's National Medical Products Administration (NMPA) to conduct human clinical trials for SRSD101, a siRNA (small interfering RNA) therapeutic for Dyslipidemia, a condition characterized by an abnormal amount of lipids in the blood. In addition, Sirius has submitted an application to begin the first clinical trial of Factor XI siRNA, a long-lasting, next-generation anticoagulant for Thromboembolic disorders, which are conditions caused by blood clots.

Sirius operates in the global biopharmaceutical market, serving patients in need of new treatment options. The company's business model revolves around the research, development, and commercialization of RNAi therapies. It generates revenue through the successful development and subsequent sale of these innovative therapies.

The company's investors include OrbiMed, Creacion Ventures, Hankang Capital, and Delos Capital, all of which are well-known institutional investors with extensive experience in the biopharmaceutical industry. The leadership team at Sirius is made up of industry veterans who have held senior positions at multinational pharmaceutical companies such as Pfizer, AstraZeneca, Novartis, Arrowhead, Dicerna, and ONYX.

Keywords: Biotech, RNAi therapies, Cardiovascular diseases, Dyslipidemia, Thromboembolic disorders, Global markets, Biopharmaceutical industry, Clinical trials, Institutional investors, Pharmaceutical companies.